Trial Profile

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nirsevimab (Primary)
Indications Respiratory syncytial virus infections
Focus Therapeutic Use
Acronyms NIRSE-GAL

Most Recent Events

17 Feb 2026 According to a Sanofi media release,data from this trial published in The Lancet Infectious Diseases Journal, and to be be presented at RSVVW 26 conference in Rome.
16 Feb 2026 Results presented at Sanofi media release.
02 May 2025 Results assessing clinical characteristics and course of respiratory syncytial virus (RSV)-related low respiratory tract infection (LRTI) hospitalizations in infants eligible for nirsevimab administration during the 2023-2024 season, published in the European Journal of Pediatrics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com